Growth Hormone Compounds

Selective ghrelin receptor agonist that releases GH without meaningfully raising cortisol or prolactin. The cleanest GHRP.

Short-acting GHRH analog that amplifies natural GH pulses. Almost always paired with a GHRP like Ipamorelin.

FDA-approved GHRH analog that specifically reduces visceral adipose tissue (VAT), originally developed for HIV-associated lipodystrophy.

C-terminal fragment of human growth hormone marketed for lipolytic effects without the IGF-1 or insulin resistance effects of full-length GH.

Oral capsule form of AOD-9604 with limited bioavailability compared to injectable form.

Classic GHRH + GHRP combination that amplifies endogenous GH pulses more than either alone.

Stack combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for amplified GH pulses and targeted visceral fat reduction.

Long-acting analog of IGF-1 with reduced IGFBP binding, producing sustained anabolic signaling.

Recombinant human growth hormone (somatropin), the therapy that secretagogues like Ipamorelin mimic indirectly.

Myostatin inhibitor investigated for muscle hypertrophy, muscular dystrophy, and body composition.

Long-acting GHRH analog with an albumin-binding linker, producing a sustained (non-pulsatile) GH/IGF-1 elevation.

29-amino-acid minimum biologically active GHRH fragment; FDA-approved as Geref in 1990 but marketing was discontinued in 2008.

Potent synthetic ghrelin receptor agonist hexapeptide approved in Japan (2006) as a GH-deficiency diagnostic.

First-generation ghrelin-receptor hexapeptide that strongly stimulates GH and appetite, with modest cortisol/prolactin effects.

Methylated GHRP-6 analog hexapeptide; a potent ghrelin-receptor agonist with additional proposed cardioprotection via CD36.

Once-daily oral ghrelin-receptor agonist that raises GH/IGF-1; Phase 3 Alzheimer's trial failed and frailty program was halted.

PEGylated 24-aa IGF-1Ec E-peptide that activates muscle satellite cells via a non-IGF-1R pathway. Grey-market use with no registered trials.

Truncated IGF-1 analog missing the first three N-terminal residues, giving much weaker IGFBP binding and a short but locally intense IGF-1R activation at the injection site.

The first oral ghrelin-receptor agonist ever approved. Single-dose diagnostic for adult growth hormone deficiency that replaces the more burdensome insulin tolerance test.

Oral ghrelin-receptor agonist approved in Japan (2021) for cancer cachexia. Phase III ROMANA-1 and ROMANA-2 met weight gain endpoints but failed functional-improvement endpoints in the US/EU.